A Phase I/II Clinical Study Evaluating the Safety and Effectiveness of BIO 300 Oral Suspension in Patients Receiving Chemoradiation Therapy for Non-Small Cell Lung Cancer (NSCLC)

Trial Profile

A Phase I/II Clinical Study Evaluating the Safety and Effectiveness of BIO 300 Oral Suspension in Patients Receiving Chemoradiation Therapy for Non-Small Cell Lung Cancer (NSCLC)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 Mar 2017

At a glance

  • Drugs BIO 300 (Primary)
  • Indications Lung disorders
  • Focus Therapeutic Use
  • Sponsors Humanetics Corporation
  • Most Recent Events

    • 03 Oct 2016 Planned number of patients changed from 30 to 36.
    • 27 Nov 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 07 Oct 2015 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health - NCT02567799).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top